Research areas

高通量膜蛋白單克隆抗體芯片

Discovering and functional accessing plasma membrane proteome

項目案例
Research areas
Brief Introduction

Using the proprietary MabArrayTM composed of 100,000 mouse monoclonal antibodies, we have successfully identified a number of novel targets for antibody-drug conjugates (ADC) including a cancer stem cell marker, in lung squamous cell carcinoma (SCC). The mAb116 was found to bind with a sub-nM affinity to this cancer stem cell marker and quickly internalized to the late lysosome after binding to the target. The ADC developed based on mAb116 (termed AMT116, i.e. mAb116-vc-MMAE) showed very potent tumor inhibition in both in vitro cytotoxity and in vivo cell-line derived xenograft (CDX) studies, and its effect was positively correlated with the expression of target. Therefore, the target identified by mAb116 is a cancer stem cell marker and deserves further development as a potential target for the development of ADC or other therapeutics.

dd1.jpg

艾比瑪特醫藥科技(上海)有限公司
上海市徐匯區桂平路333號聚科生物園區1號樓1-3層

郵箱:market@ab-mart.com

應聘職位:hr@ab-mart.com

訂購專線:4006-123-828

銷售電話:13162127138

技術支持:13162477137

總機:021-34695901


wx.png

      微信客服

郵箱:market@ab-mart.com

總機:021-34695901

熱線:13166434152 

訂購專線:4006-123-828

wx.png

微信客服

滬ICP備17056956號-2    艾比瑪特醫藥科技(上海)有限公司